Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Palm, Frederick ^a   Kraus, Martin ^b   Safer, Anton ^c   Wolf, Joachim ^a   Becher, Heiko ^c   Grau, Armin J ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b Klinikum   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Atrial fibrillation; Cardioembolic stroke; Oral anticoagulation

Indexed keywords

ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ANTICOAGULANT AGENT;

ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EARLY INTERVENTION; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; RANKIN SCALE; REGISTER; STROKE PATIENT; TIME TO TREATMENT; TRANSIENT ISCHEMIC ATTACK; VERY ELDERLY; YOUNG ADULT; ATRIAL FIBRILLATION; COMPLICATION; DISEASE MANAGEMENT; EPIDEMIOLOGY; GERMANY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DISEASE MANAGEMENT; FEMALE; GERMANY; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; STROKE; TREATMENT OUTCOME;

EID: 84908083486     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0199-7     Document Type: Article

References (35)

1. Hajat C, Heuschmann PU, Coshall C, Padayachee S, Chambers J, Rudd AG, Wolfe CD. Incidence of aetiological subtypes of stroke in a multi-ethnic population based study: the south London stroke register. J Neurol Neurosurg Psychiatry 2011, 82(5):527-533. 10.1136/jnnp.2010.222919, 20974649.
2. Palm F, Urbanek C, Wolf J, Buggle F, Kleemann T, Hennerici MG, Inselmann G, Hagar M, Safer A, Becher H, Grau AJ. Etiology, risk factors and sex-differences in ischemic stroke in the Ludwigshafen stroke study (LuSSt), a population-based stroke registry. Cerebrovasc Dis 2012, 33(1):64-68. 10.1159/000333417.
3. Jickling GC, Stamova B, Ander BP, Zhan X, Liu D, Sison SM, Verro P, Sharp FR. Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location. Stroke 2012, 43(8):2036-2041. 10.1161/STROKEAHA.111.648725, 22627989.
4. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the framingham heart study. Circulation 2004, 110(9):1042-1046. 10.1161/01.CIR.0000140263.20897.42, 15313941.
5. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009, 104(11):1534-1539. 10.1016/j.amjcard.2009.07.022, 19932788.
6. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J, Moroney J, McCormack PM, Daly L, Fitz-Simon N, Harris D, Horgan G, Williams EB, Furie KL, Kelly PJ. Stroke associated with atrial fibrillation-incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis 2010, 29(1):43-49. 10.1159/000255973, 19893311.
7. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001, 32(12):2735-2740. 10.1161/hs1201.100209, 11739965.
8. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001, 32(11):2559-2566. 10.1161/hs1101.098524, 11692017.
9. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med 2012, 172(8):623-631. discussion 631-623, 10.1001/archinternmed.2012.121, 22450212.
10. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012, 43(12):3298-3304. 10.1161/STROKEAHA.112.673558, 23150654.
11. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, Kirchhof P. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European heart rhythm association [EHRA], endorsed by the european society of cardiology [ESC] working group on thrombosis. Thromb Haemost 2011, 106(6):997-1011. 10.1160/TH11-10-0690, 22048796.
12. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, Caso V, Micheli S, Bertolani L, Venti M, Palmerini F, Biagini S, Comi G, Previdi P, Silvestrelli G. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008, 39(8):2249-2256. 10.1161/STROKEAHA.107.510321, 18535273.
13. McGrath ER, Kapral MK, Fang J, Eikelboom JW, O'Conghaile A, Canavan M, O'Donnell MJ. Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation?. Stroke 2012, 43(8):2048-2054. 10.1161/STROKEAHA.112.654145, 22618379.
14. Palm F, Urbanek C, Rose S, Buggle F, Bode B, Hennerici MG, Schmieder K, Inselmann G, Reiter R, Fleischer R, Piplack KO, Safer A, Becher H, Grau AJ. Stroke incidence and survival in ludwigshafen am rhein, Germany: the Ludwigshafen stroke study (LuSSt). Stroke 2010, 41(9):1865-1870. 10.1161/STROKEAHA.110.592642, 20689086.
15. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976, 54(5):541-553. 1088404.
16. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the european society of cardiology (ESC). Eur Heart J 2010, 31(19):2369-2429. 10.1093/eurheartj/ehq278, 20802247.
17. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European heart rhythm association. Eur Heart J 2012, 33(21):2719-2747. 10.1093/eurheartj/ehs253, 22922413.
18. Banks JL, Marotta CA. Outcomes validity and reliability of the modified rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007, 38(3):1091-1096. 10.1161/01.STR.0000258355.23810.c6, 17272767.
19. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol 1989, 46(6):660-662. 10.1001/archneur.1989.00520420080026, 2730378.
20. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139(2):137-147. 10.7326/0003-4819-139-2-200307150-00013, 12859163.
21. Kaarisalo MM, Immonen-Raiha P, Marttila RJ, Salomaa V, Kaarsalo E, Salmi K, Sarti C, Sivenius J, Torppa J, Tuomilehto J. Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke 1997, 28(2):311-315. 10.1161/01.STR.28.2.311, 9040681.
22. Andersen KK, Olsen TS. Reduced poststroke mortality in patients with stroke and atrial fibrillation treated with anticoagulants: results from a danish quality-control registry of 22,179 patients with ischemic stroke. Stroke 2007, 38(2):259-263. 10.1161/01.STR.0000254622.52483.03, 17194876.
23. Leistner S, Benik S, Laumeier I, Ziegler A, Nieweler G, Nolte CH, Heuschmann PU, Audebert HJ. Secondary prevention after minor stroke and TIA - usual care and development of a support program. PLoS One 2012, 7(12):e49985. 10.1371/journal.pone.0049985, 23284630.
24. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke 2012, 43(7):1795-1799. 10.1161/STROKEAHA.111.630731, 22539546.
25. Azoulay L, Dell'aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014, 35(28):1991-1887. 10.1093/eurheartj/eht499.
26. McGrath ER, Kapral MK, Fang J, Eikelboom JW, O'Conghaile A, Canavan M, O'Donnell MJ. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology 2013, 81(9):825-832. 10.1212/WNL.0b013e3182a2cc15, 23902702.
27. Heyden S, Heiss G, Heyman A, Tyroler AH, Hames CG, Patzschke U, Manegold C. Cardiovascular mortality in transient ischemic attacks. Stroke 1980, 11(3):252-255. 10.1161/01.STR.11.3.252, 7394861.
28. Clappers N, Brouwer MA, Verheugt FW. Antiplatelet treatment for coronary heart disease. Heart 2007, 93(2):258-265. 10.1136/hrt.2005.071209, 17228079.
29. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009, 374(9706):1967-1974. 10.1016/S0140-6736(09)61751-7, 20006130.
30. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002, 360(9327):109-113. 10.1016/S0140-6736(02)09409-6, 12126819.
31. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in " real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013, 61(22):2264-2273. 10.1016/j.jacc.2013.03.020, 23562920.
32. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011, 32(22):2781-2789. 10.1093/eurheartj/ehr113, 21551462.
33. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012, 172(5):397-402. 10.1001/archinternmed.2011.1666, 22231617.
34. EAFT (european atrial fibrillation trial) study group. Lancet 1993, 342(8882):1255-1262. 7901582.
35. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012, 11(3):225-231. 10.1016/S1474-4422(12)70017-0, 22305462.